Acadia Pharmaceuticals (ACAD) PT Raised to $42 at Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $28.62 -2.82%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Join SI Premium – FREE
Cantor Fitzgerald analyst Sarah James raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $42.00 (from $36.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Mitsubishi Electric (6503:JP) (MIELY) PT Raised to JPY7,400 at Nomura/Instinet
- Medipal Holdings Corp (7459:JP) PT Lowered to JPY3,080 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
